Breaks Categories: News

MondayJul 15, 2024 10:40 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting recent study results. According to the announcement, the successful in-vivo preclinical results are from SCNI’s innovative anti IL-17A/F VHH antibody fragment (“NanoAb”), which is being studied as a local, first-of-its-kind, intralesional biological treatment for from mild to moderate plaque psoriasis. An estimated million patients are diagnosed with plaque psoriasis in the United States, Japan and Europe. Scinai's product candidate is designed to address the major shortcomings of…

Continue Reading

FridayJul 12, 2024 2:32 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Management Slated to Participate in Upcoming Emerging Growth Conference

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will be participating in next week’s Emerging Growth Conference. According to the announcement, members of Clene’s management team will be presenting at the one-day conference, which is scheduled for July 18, 2024. The online presentation, which will begin at 4:45 p.m. EDT, will include a corporate update as well as a question-and-answer session. A webcast of the presentation will be available on the…

Continue Reading

ThursdayJul 11, 2024 1:16 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Prepares to Submit Briefing Book to FDA, Looks to Obtain Key Feedback Regarding NDA for CNM-Au8 in ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is in the process of submitting a briefing book to the U.S. Food and Drug Administration (“FDA”). The company anticipates submitting the book by July 13, 2024, in advance of the FDA granting a Type C interaction. According to the announcement, the purpose of the interaction between Clene and the FDA is to obtain key feedback on the potential path to submission of…

Continue Reading

TuesdayJul 09, 2024 4:01 pm

BioMedNewsBreaks — VolitionRx Limited (NYSE American: VNRX) appoints PharmaVentures for Capture PCR™ and Oncology Portfolio Licensing

VolitionRx Limited (NYSE American: VNRX), a multi-national epigenetics company focused on saving lives and improving outcomes for people and animals with life-altering diseases, announced the engagement of PharmaVentures Ltd (“PharmaVentures”) to act as an advisor. PharmaVentures will provide strategic advice and transactional support as Volition works towards securing licensing deals with industry leaders for both Nu.Q(R) Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR™ – a novel detection method for liquid biopsy in cancer and potentially other diseases. “PharmaVentures is a respected, international advisory company with a proven track record…

Continue Reading

TuesdayJul 09, 2024 11:10 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team

  Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has announced that four new executives will be joining the company’s management team. The four new leaders include Mark White as chief business officer; Alexander Morris, PhD, as director of strategic communications; Hilda Maibach as senior vice president of statistics; and Blake Jensen as head of quality. White is currently serving as a board member and has held positions of increasing responsibility at Pfizer, Bracco, Abbott and Bayer. Most recently, he was vice president of worldwide…

Continue Reading

TuesdayJul 09, 2024 10:45 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Effect 1-for-20 Reverse Stock Split

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will effect a 1-for-20 reverse stock split at 12:01 a.m. ET on July 11, 2024. According to the announcement, Clene’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 185634201 and the company’s existing symbol CLNN at the beginning of trading on July 11. The reverse stock split, for which Equiniti Trust Company LLC…

Continue Reading

FridayJul 05, 2024 2:55 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enters Securities Purchase Agreements Worth Estimated $1.98M

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements, which are for the purchase and sale of 1,425,000 shares of common stock, are comprised of a registered direct offering and warrants. The offering and warrants are to purchase up to 1,425,000 shares of common stock in a concurrent private placement at a combined purchase price of $1.39 per share. The offering is expected to close today, subject to customary closing…

Continue Reading

FridayJul 05, 2024 11:29 am

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Amends Original Material Change Report, Files Amended and Restated MCR

  FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has filed an amended and restated material change report. According to the announcement, the report amended the disclosure in Section 5.1 of the original MCR. “The amended and restated material change report is being filed to provide additional disclosure with respect of the private placement offering of Class A multiple voting shares of the company that closed on Dec. 5, 2023,” stated the company in the press release. “The amended and restated MCR can be found on…

Continue Reading

TuesdayJul 02, 2024 10:53 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting on its financial results for the quarter ended March 31, 2024; the company also released a business update. Notable financial numbers include R&D expenses for the three-month period totaling $1,568,000; marketing, general and administrative expenses totaling $484,000; financial income totaling $231,000; and net loss reported at $2,159,000; the company also reported cash and cash equivalents and short-term deposits of $4,826,000 as of March 31, 2024. Business highlights include raising $1.69 million in gross proceeds…

Continue Reading

TuesdayJul 02, 2024 10:25 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Expands E-Commerce Program in China

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that it has expanded its e-commerce development program in China through a new agreement with a leading Chinese healthcare and nutritional products marketing and distribution services partner (the “marketing partner”). According to the update, the marketing partner will provide NextPlat with a full range of creative content, brand marketing and product sales and distribution services and support the company’s exclusive joint e-commerce development agreement with OPKO Health Europe , a subsidiary of OPKO Health, Inc. (NASDAQ: OPK). “Our unique e-commerce development program was created to provide American companies with turn-key…

Continue Reading